United Therapeutics (NASDAQ:UTHR) Given New $643.00 Price Target at Royal Bank Of Canada

United Therapeutics (NASDAQ:UTHR) had its price target raised by Royal Bank Of Canada from $587.00 to $643.00 in a research report report published on Thursday,Benzinga reports. The firm currently has an outperform rating on the biotechnology company’s stock.

UTHR has been the subject of a number of other research reports. TD Cowen upped their price objective on United Therapeutics from $525.00 to $575.00 and gave the company a “buy” rating in a research note on Wednesday. Morgan Stanley set a $447.00 price objective on shares of United Therapeutics in a report on Wednesday, October 29th. Bank of America reiterated a “neutral” rating on shares of United Therapeutics in a research note on Wednesday. UBS Group restated a “buy” rating on shares of United Therapeutics in a research note on Tuesday, February 17th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $533.55.

United Therapeutics Stock Performance

United Therapeutics stock opened at $503.60 on Thursday. United Therapeutics has a fifty-two week low of $266.98 and a fifty-two week high of $537.19. The firm’s 50-day simple moving average is $484.64 and its 200 day simple moving average is $444.51. The stock has a market cap of $21.69 billion, a PE ratio of 18.05, a price-to-earnings-growth ratio of 2.85 and a beta of 0.85.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping the consensus estimate of $6.78 by $0.92. The firm had revenue of $790.20 million for the quarter, compared to analysts’ expectations of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same quarter last year, the firm earned $6.19 EPS. As a group, analysts predict that United Therapeutics will post 24.48 EPS for the current fiscal year.

Insider Activity

In related news, COO Michael Benkowitz sold 14,440 shares of the company’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $472.13, for a total value of $6,817,557.20. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Paul A. Mahon sold 8,300 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $476.34, for a total transaction of $3,953,622.00. Following the completion of the sale, the executive vice president directly owned 36,781 shares in the company, valued at $17,520,261.54. This represents a 18.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 407,954 shares of company stock worth $197,601,528. 10.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Torren Management LLC purchased a new position in shares of United Therapeutics in the 4th quarter worth about $26,000. Activest Wealth Management lifted its position in United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after buying an additional 56 shares during the last quarter. Entrust Financial LLC purchased a new stake in United Therapeutics in the fourth quarter worth approximately $31,000. Wilmington Savings Fund Society FSB grew its position in United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 49 shares during the last quarter. Finally, Harbor Capital Advisors Inc. purchased a new position in shares of United Therapeutics during the fourth quarter worth approximately $48,000. Institutional investors own 94.08% of the company’s stock.

Key United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Q4 EPS beat and reiterated growth ambition — United Therapeutics reported $7.70 EPS (vs. $6.78 expected) and posted record full‑year revenue of $3.18B, supporting upside momentum. Read More.
• Positive Sentiment: Analysts raised price targets materially — H.C. Wainwright (PT to $600, buy), Oppenheimer (PT to $600, outperform) and RBC (PT to $643, outperform) lifted targets after the print, adding potential upside for the stock. Read More. Read More. Read More.
• Positive Sentiment: Management is targeting a ~$4B revenue run‑rate by 2027 tied to upcoming product launches — a clear multi‑year growth thesis that supports analyst optimism. Read More.
• Neutral Sentiment: Bullish options flow around the print — elevated call buying suggests traders were positioning for upside or volatility, which can amplify moves but is not a fundamental change. Read More.
• Neutral Sentiment: Analyst views remain mixed — some firms (BTIG, Morgan Stanley) kept Hold ratings and Morgan Stanley’s $447 target signals caution even as others raise targets, so expect divergent analyst notes ahead. Read More.
• Negative Sentiment: Revenue missed the quarter — $790.2M vs. ~ $814.8M consensus, which prompted earlier weakness and highlights top‑line execution risk. Read More.
• Negative Sentiment: Significant insider selling — the COO sold large blocks (14,440 shares) and a director sold additional lots in February; repeated insider disposals can undermine confidence even if they may be for diversification. Read More.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.